225 related articles for article (PubMed ID: 15309513)
21. Chemoprevention of colorectal cancer.
Das D; Arber N; Jankowski JA
Digestion; 2007; 76(1):51-67. PubMed ID: 17947819
[TBL] [Abstract][Full Text] [Related]
22. Chemoprevention of colorectal cancer: feasibility in everyday practice?
Herszényi L; Farinati F; Miheller P; Tulassay Z
Eur J Cancer Prev; 2008 Nov; 17(6):502-14. PubMed ID: 18941372
[TBL] [Abstract][Full Text] [Related]
23. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.
Hurlstone DP; Karajeh M; Sanders DS; Drew SK; Cross SS
Am J Gastroenterol; 2005 Jun; 100(6):1283-9. PubMed ID: 15929758
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial.
Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
BMC Cancer; 2020 Oct; 20(1):1043. PubMed ID: 33121471
[TBL] [Abstract][Full Text] [Related]
25. Aberrant crypt foci in colon cancer epidemiology.
Khare S; Chaudhary K; Bissonnette M; Carroll R
Methods Mol Biol; 2009; 472():373-86. PubMed ID: 19107443
[TBL] [Abstract][Full Text] [Related]
26. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.
Higurashi T; Hosono K; Endo H; Takahashi H; Iida H; Uchiyama T; Ezuka A; Uchiyama S; Yamada E; Ohkubo H; Sakai E; Maeda S; Morita S; Natsumeda Y; Nagase H; Nakajima A
BMC Cancer; 2012 Sep; 12():413. PubMed ID: 22992267
[TBL] [Abstract][Full Text] [Related]
27. Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci.
Kim KP; Whitehead C; Piazza G; Wargovich MJ
Anticancer Res; 2004; 24(3a):1805-11. PubMed ID: 15274359
[TBL] [Abstract][Full Text] [Related]
28. [Chemoprevention of colorectal cancer].
Herszényi L; Juhász M; Prónai L; Tulassay Z
Orv Hetil; 2004 Mar; 145(12):603-10. PubMed ID: 15119114
[TBL] [Abstract][Full Text] [Related]
29. Aberrant crypt foci: what we know and what we need to know.
Gupta AK; Pretlow TP; Schoen RE
Clin Gastroenterol Hepatol; 2007 May; 5(5):526-33. PubMed ID: 17433788
[TBL] [Abstract][Full Text] [Related]
30. Early events in human colorectal carcinogenesis. Aberrant crypts and microadenoma.
Roncucci L
Ital J Gastroenterol; 1992; 24(9):498-501. PubMed ID: 1489980
[TBL] [Abstract][Full Text] [Related]
31. Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs.
Hilmi I; Goh KL
Chin J Dig Dis; 2006; 7(1):1-6. PubMed ID: 16412030
[TBL] [Abstract][Full Text] [Related]
32. Oncoprotein coexpression in human aberrant crypt foci and minute polypoid lesions of the large bowel.
Shpitz B; Bomstein Y; Shalev M; Liverant S; Kaufman Z; Klein E; Mekori Y; Bernheim J
Anticancer Res; 1999; 19(4B):3361-6. PubMed ID: 10652634
[TBL] [Abstract][Full Text] [Related]
33. Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
Stevens RG; Pretlow TP; Hurlstone DP; Giardina C; Rosenberg DW
Cancer Prev Res (Phila); 2008 Aug; 1(3):215-6; author reply 216. PubMed ID: 19138959
[No Abstract] [Full Text] [Related]
34. Significance and role of early-lesions in experimental colorectal carcinogenesis.
Mori H; Hata K; Yamada Y; Kuno T; Hara A
Chem Biol Interact; 2005 Jun; 155(1-2):1-9. PubMed ID: 15904905
[TBL] [Abstract][Full Text] [Related]
35. Endocytoscopy can identify dysplasia in aberrant crypt foci of the colorectum: a prospective in vivo study.
Cipolletta L; Bianco MA; Rotondano G; Piscopo R; Meucci C; Prisco A; Cipolletta F; de Gregorio A; Salvati A
Endoscopy; 2009 Feb; 41(2):129-32. PubMed ID: 19214891
[TBL] [Abstract][Full Text] [Related]
36. Histomorphology of aberrant crypt foci in colorectal carcinoma.
Norlida AO; Phang KS
Malays J Pathol; 2010 Dec; 32(2):111-6. PubMed ID: 21329182
[TBL] [Abstract][Full Text] [Related]
37. Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa.
Holt PR; Bresalier RS; Ma CK; Liu KF; Lipkin M; Byrd JC; Yang K
Cancer; 2006 Jan; 106(2):287-96. PubMed ID: 16353199
[TBL] [Abstract][Full Text] [Related]
38. Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm.
Sakai E; Takahashi H; Kato S; Uchiyama T; Hosono K; Endo H; Maeda S; Yoneda M; Taguri M; Nakajima A
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1918-24. PubMed ID: 21750169
[TBL] [Abstract][Full Text] [Related]
39. The natural history of aberrant crypt foci.
Schoen RE; Mutch M; Rall C; Dry SM; Seligson D; Umar A; Pinsky P
Gastrointest Endosc; 2008 Jun; 67(7):1097-102. PubMed ID: 18178205
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers in colorectal cancer.
Owen RW
IARC Sci Publ; 2001; 154():101-11. PubMed ID: 11220650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
